AnaptysBio

AnaptysBio is a hybrid biotech: it owns one of the most lucrative biotech royalty streams in the industry — Jemperli (dostarlimab) royalties from GSK — plus a wholly-owned clinical-stage immunology pipeline that has two pivotal Phase 2b readouts in the next 12 months. Jemperli is GSK anti-PD-1 antibody, approved for endometrial cancer and currently running multiple Phase 3 readouts in colorectal and other solid tumors. AnaptysBio receives tiered royalties (8-25 percent) plus milestones — Jemperli is on track to exceed 1.5 billion dollars in 2026 sales with consensus 3-4 billion dollars peak. That single royalty stream is worth approximately 1.5-2.0 billion dollars on a discounted-cash-flow basis — covering most or all of the current 1.8 billion dollar market cap.

The wholly-owned pipeline is the upside. Rosnilimab is a depleter-PD-1 agonist antibody (mechanistically opposite to Jemperli) entering Phase 2b readouts in rheumatoid arthritis (RA) in Q4/2026 and ulcerative colitis (UC) in Q2/2027. The Phase 2a RA data showed sustained response durable to 28 weeks with 80 percent ACR50 maintenance — comparable to top-tier biologics. ANB032 (BTLA agonist) is in Phase 2b for ulcerative colitis. ANB033 (CD122 antagonist) entered Phase 1 for celiac disease in Q1/2026. The setup is a binary catalyst-rich 18-month window with a 22 percent short interest at the time of writing — among the highest in biotech for a name with multiple positive readouts ahead.

AnaptysBio has one of the most concentrated biotech-specialist shareholder registers among mid-cap names. Baker Brothers Advisors (the Felix and Julian Baker family office that runs roughly 30 billion dollars in healthcare-only assets) holds approximately 11.4 percent and added in Q1/2026. Avoro Capital Advisors (Behzad Aghazadeh, one of the highest-conviction biotech specialists) holds 8.2 percent, RA Capital Management 6.8 percent (Peter Kolchinsky), and Adage Capital Partners 5.1 percent. The Baker Brothers position is particularly notable: Baker Brothers has historically been the dominant smart-money signal for the next wave of biotech royalty-and-pipeline plays.

Insider activity has been mixed but skewed buying. CFO Eric Loumeau purchased 350 thousand dollars at 58 dollars in February 2026, and CEO Daniel Faga has not sold any vested options since taking the role. The recommendation column shows strong-buy consensus from 8 analysts with 12-month price target of 84.36 dollars (33.6 percent upside) and a high-target of 130 dollars from Cantor Fitzgerald — most bullish on the rosnilimab probability of success.

At 63 dollars AnaptysBio trades at 1.84 billion dollars market cap, 7.9x trailing sales, and 10.7x forward earnings (driven by the Jemperli royalty stream). The intrinsic-value framework splits into two parts. The Jemperli royalty discounted cash flow (consensus peak 3.5 billion dollar Jemperli sales, 15 percent blended royalty rate, 9 percent discount rate, 12-year patent life) values the royalty alone at approximately 1.7-2.0 billion dollars. The wholly-owned pipeline at current probability-weighted NPV (rosnilimab RA at 35 percent probability of approval and 2-3 billion dollar peak, UC at 30 percent, ANB032 at 25 percent) computes to approximately 800-1,000 million dollars on a risk-adjusted basis. Sum-of-the-parts fair value: 2.5-3.0 billion dollars or 85-105 dollars per share. The bear case (rosnilimab Phase 2b fails, Jemperli royalty pressured by Keytruda biosimilars) supports 45-50 dollars per share, roughly 25 percent downside.

1. April 2026: Jemperli Phase 3 metastatic colorectal cancer Phase 3 readout (PERSEUS-3 trial) — positive data would add roughly 600-800 million dollars to peak sales estimate and re-rate the royalty stream value
2. Q4 2026: Rosnilimab Phase 2b rheumatoid arthritis topline readout — the highest-impact binary catalyst, primary endpoint 52-week ACR50 maintenance versus placebo and a withdrawal arm
3. Q2 2027: Rosnilimab Phase 2b ulcerative colitis topline readout — secondary high-impact binary catalyst for the IBD expansion thesis

AnaptysBio is one of the highest-conviction biotech pipeline-plus-royalty setups I see at this market cap. I size at 1.5 percent portfolio weight — conservative because of the binary nature of the upcoming rosnilimab readouts. The unique aspect of this setup is the Jemperli royalty floor: even in a worst-case rosnilimab failure, the royalty stream alone is worth 80-100 percent of the current stock price, meaning the downside is bounded by the value of the royalty. The Baker Brothers 11.4 percent position is the single most important smart-money signal — they have historically been right on the biotech-royalty-plus-pipeline thesis (e.g., Madrigal, Acceleron). I add aggressively on any drawdown to 50 dollars and trim 30 percent at 90 dollars to lock in the rerate to the consensus high end. If the April 2026 Jemperli Phase 3 colorectal readout is positive, I add another 0.5 percent ahead of the rosnilimab readout. If it is negative, I hold the position size and wait for rosnilimab Q4/2026 as the primary catalyst.